Review Article

Review of robot-assisted partial nephrectomy in modern practice

Aaron M. Potretzke, John Weaver, Brian M. Benway

Washington University School of Medicine, Division of Urologic Surgery, St. Louis, Missouri, USA

Abstract

Partial nephrectomy (PN) is currently the standard treatment for T1 renal tumors. Minimally invasive PN offers decreased blood loss, shorter length of stay, rapid convalescence, and improved cosmesis. Due to the challenges inherent in laparoscopic partial nephrectomy, its dissemination has been stifled. Robot-assisted partial nephrectomy (RAPN) offers an intuitive platform to perform minimally invasive PN. It is one of the fastest growing robotic procedures among all surgical subspecialties. RAPN continues to improve upon the oncological and functional outcomes of renal tumor extirpative therapy. Herein, we describe the surgical technique, outcomes, and complications of RAPN.

Copyright: The Authors.

Received: 06 March 2015; Accepted after revision: 27 March 2015; Published: 04 April 2015

Author for correspondence: Aaron M. Potretzke, MD, 4960 Children’s Place, Campus Box 8242, Saint Louis, MO 63110, USA. E-mail: potretzkea@wudosis.wustl.edu

How to cite: Potretzke AM, Weaver J, Benway BM. Review of robot-assisted partial nephrectomy in modern practice. Journal of Kidney Cancer and VHL 2015;2(2):30-44. Doi: http://dx.doi.org/10.15586/jkcvhl.2015.23

Introduction

Kidney cancer incidence continues to rise in the United States (U.S.) (1). The rise in incidence is at least partially attributed to the increased detection of incidental masses with more prevalent imaging (2). In 2015, an estimated 61,560 new cancer cases and 14,080 deaths will be attributed to kidney cancer in the U.S. (3). The majority of cases (> 60%) are small renal masses, < 4 cm (4).

It is well established, based on retrospective, and prospective randomized trials, that renal function after partial nephrectomy (PN) is superior when compared with radical nephrectomy (RN) (5,6). What is still unclear is whether this translates to a survival benefit, as conflicting data abounds and is debated (7-11). The most recent iteration of the American Urological Association’s guidelines references the advantages of PN and recommends it as first-line therapy for all T1a cancers, and T1b cancers in many settings (12). In accordance with this recommendation, PN utilization has increased over the past decade (13). At some centers, PN is employed for the treatment of T1a tumors nearly 90% of the time (14). In 2008, robot-assisted partial nephrectomy (RAPN) was the fastest growing robotic procedure among all surgical specialties worldwide (15). Also, Patel et al showed that over a time span corresponding to the dissemination of robotic technology (2000–2011), open RN rates decreased by 33%, PN rates increased by 15%, and RAPN rates increased to 14% at university practices and 10% at non-university practices (16).
Progression of surgical treatment has moved from open partial nephrectomy (OPN), to laparoscopic partial nephrectomy (LPN), and most recently RAPN. LPN has been deemed equally effective as OPN in terms of long-term oncological and functional outcomes (17, 18). Moreover, LPN was found to result in reduced blood loss, shorter hospital stays, superior cosmesis, and more rapid convalescence when compared to OPN. The main deterrent that has hindered the widespread adoption of LPN is the technically demanding nature of the procedure; it is therefore underutilized (19). As a result, RAPN has been studied extensively in recent years with the hope of finding a minimally invasive nephron sparing approach with a learning curve more manageable than that of LPN. RAPN appears to fit this niche as the quoted learning curve for RAPN is approximately 25 cases, whereas the learning curve for LPN is estimated to be > 200 cases (20-22).

Surgeon preference also dictates the number of robotic arms employed; either a three- or four-arm configuration can be used (Figure 1). The use of the fourth arm does provide the surgeon at the console with more control of retraction, removing some delegation to the bedside assistant.

There are multiple techniques that can be utilized in clamping the renal hilar vessels. They can be clamped individually (starting with the artery) using laparoscopic bulldog clamps or en bloc using a laparoscopic Satinsky clamp. The latter requires placement of a dedicated port. Robotic bulldog clamps provide the surgeon additional autonomy, in lieu of having to depute the assistant to the delicate task of hilar occlusion.

Minimizing warm ischemia time

Multiple authors have demonstrated potential deleterious effects of prolonged warm ischemia time (WIT) (29-31) although its significance relative to the volume of parenchyma preserved is debated (32). Although the exact threshold is unknown, the common goal is < 30 minutes. Several novel techniques have been proposed. First, “early-unclamping” can decrease WIT. In early-unclamping, the intrarenal or hilar blood vessels are unclamped after the tumor is excised and just a preliminary repair of the deep nephrectomy bed has been performed. The parenchymal repair is performed while off clamp (33). Peyronnet et al. demonstrated a decrease in WIT across 430 patients from 22.3 to 16.7 minutes (p < 0.0001). Blood loss was greater in the early unclamping group (369 vs. 240 mL, p = 0.001) (34). Next, the use of barbed suture has been proposed. Sammon et al. demonstrated a reduction in WIT from 24.7 to 18.5 minutes (p = 0.008) by using a V-Loc (Covidien, Mansfield, MA, USA) barbed suture rather than individually placed Vicryl sutures.
Another evolutionary technique is referred to as “zero-ischemia.” A preoperative computed tomography 3-dimensional angiogram is obtained. Induced hypotension is initiated by the anesthesiologist. The surgeon identifies and controls only the tertiary or higher-order arterial branches that feed the “tumor plus margin”, and thus, no ischemia is experienced by the renal remnant (35). Finally, “off clamp” procedures have been pursued. Tanagho et al. described a series of 29 clamped and 29 off clamp RAPN. Estimated blood loss was higher in the off clamp group (146 mL vs. 104 mL, p = 0.04), while mean change in estimated glomerular filtration rate (eGFR) was less (-4.9 vs. -11.7 mL/min, p = 0.03) (36).

**Surgical defect repair**

For renorrhaphy, either an absorbable monofilament or a V-Loc suture is typically used in a running fashion to repair large blood vessels and collecting system defects. A secondary layer may also be used to further approximate the deep layer of the resection bed. Next the renal capsule’s outer layer is closed with large absorbable sutures and needles. The Washington University technique of “sliding-clip renorrhaphy,” relies upon the use of Weck Hem-o-Lok clips (Teleflex, Morrisville, NC, USA), placed on Vicryl suture, on either side of the defect and then slid into place by the surgeon, to exert tension upon the repair (Figure 2) (25). The Hem-o-Lok clips are generally reinforced with Lapra-Ty clips (Ethicon, Cincinnati, OH, USA) to prevent backsliding of the clips. This technique is ideally suited for RAPN, as the robotic instrumentation affords the surgeon the requisite precision in dictating the degree of tension placed on the repair, effectively eliminating the need for placement of surgical bolsters in the renal defect to achieve tight closure. While other methods of renorrhaphy have been suggested, the closing tension in sliding clip renorrhaphy is superior and is relatively facile to perform (37).

**Preoperative imaging**

Over the last several years, interest has grown in the development of systems to quantify and compare renal masses (e.g. PADUA, R.E.N.A.L., and C-index) (38-40). In 2009, Kutikov and Uzzo published their work on the R.E.N.A.L nephrometry score (RNS) (40). The components include: (R)adius (tumor size as diameter), (E)xophytic/endophytic properties, (N)earness to the collecting system, (A)nterior/posterior, and (L)ocation relative to the polar line. Since its inception, it was been well studied. RNS has been associated with type of surgical therapy undertaken (41,42) operative time (43) estimated blood loss (44), WIT (45), leak rate (41,46), other complications (43,47) and length of stay (48).
The benefit of preoperative assessment with tumor quantification tools is not yet entirely clear in RAPN. Some authors have found it to be related to percent functional volume preservation, nadir eGFR (49), WIT and collecting system entry (45). However, others have demonstrated either no predictive value (50), or no greater performance than a more traditional metric such as tumor size (51).

**Recent advancements**

The robotic ultrasound probe (Aloka, Tokyo, Japan) can be used once the tumor is exposed in order to delineate precise tumor borders for dissection. With the da Vinci Si platform, TilePro software (Intuitive Surgical, Sunnyvale, CA, USA) can be employed for visualization of the real-time ultrasonic images. Further, this affords the surgeon greater independence from bedside assistance and obviating the need to leave the console to view images (52).

Another emerging advancement is the use of near-infrared fluorescence imaging. The component enabled in the newer da Vinci platforms is Firefly (Intuitive Surgical, Sunnyvale, CA, USA). The fluorescent marker often used is indocyanine green (ICG; Akorn, Lake Forest, IL, USA). Once a selected vessel branch is clamped, the ICG is given (5-7.5 mg), and the Firefly enacted at the console. Tissues receiving blood flow will turn fluorescent green while the ischemic tumor (and collateral tissue) will appear pale. McClintock et al. demonstrated increased renal function in the short term when compared with non-selective arterial clamping and without the use of Firefly (53).

**Outcomes**

**Comparison to laparoscopic partial nephrectomy**

Numerous studies now exist in the literature which favorably compare RAPN to LPN (54–60). In 2015, Choi et al. performed a meta-analysis of 23 studies, comprised of 2240 patients which compared RAPN to LPN. The authors found no difference in the following perioperative outcomes: Clavien grade 1-2 complications (p = 0.62), Clavien grade 3-5 complications (p = 0.78), change in serum creatinine (p = 0.65), operative time (p= 0.35), estimated blood loss (p=0.76), and positive surgical margins (p = 0.75). Patients undergoing RAPN had a lower rate of conversion to open (p = 0.02) or radical surgery (p = 0.0006), shorter WIT (p = 0.005), smaller change in eGFR (p= 0.03), and shorter LOS (p = 0.004) (61). No randomized trial has been done comparing the two approaches. However, given the above evidence and the

---

**Figure 2.** Sliding clip renorrhaphy. Solid lines indicate the direction of force applied to slide clips into position. Dashed line indicates the Hem-o-Lok clip that was placed extracorporeally on the end of the suture.
inherent improvement of sewing with robotic-assistance, the robotic approach has garnered favor.

“Trifecta”

A recently introduced concept used to evaluate PN outcomes is the “trifecta.” (62,63). The three outcomes assessed are: negative tumor margins, functional preservation, and no urologic complications. In the original paper describing the “trifecta”, Hung et al. divided patients retrospectively into four chronological eras, referred to as the discovery era (September 1999 to December 2003; n = 139), the conventional hilar-clamping era (January 2004 to December 2006; n = 213), the early-unclamping era (January 2007 to November 2008; n = 104) and the zero-ischemia era (which was performed at the authors' institution from March 2010 to October 2011; n = 78).

Over the four eras studied, the tumors trended toward being larger (2.9, 2.8, 3.1 and 3.3 cm for the discovery, conventional hilar-clamping, early-unclamping and zero-ischemia eras, respectively; P = 0.08), but the estimated percentage of kidney function preserved was similar (89%, 90%, 90%, and 88%, respectively; P = 0.3). More recent eras were associated with increasingly complex tumors, with tumors more likely to be >4 cm in size (P = 0.03), located centrally (P < 0.009) or hilar (P < 0.0001). Nevertheless, the WITs decreased serially at 36, 32, 15 and 0 min for the discovery, conventional hilar-clamping, early-unclamping and zero-ischemia eras, respectively (P < 0.0001). The renal function outcomes were superior in the contemporary eras, with fewer patients experiencing declines (P < 0.0001). The positive surgical margin rates were uniformly low (P = 0.7), and urological complications tended to be fewer in the more recent eras (P = 0.01). Trifecta outcomes were achieved more commonly in the recent eras and were 45%, 44%, 62%, and 68% for the discovery, conventional hilar-clamping, early-unclamping and zero-ischemia eras, respectively (P = 0.0002). In a more recent multi-institutional study, Zargar et al. reported on 1185 RAPN and 646 LPN. The authors reported a trifecta in 70% of RAPN cases, compared to 33% of LPN. WIT (18 vs. 26 min), complication rate (16.2 vs. 25.9%), and positive surgical margin (PSM; 3.2 vs. 9.7%) each favored RAPN (54). Table 1 presents the outcomes of the largest series in RAPN.

Oncological outcomes

In the largest series reporting oncological outcomes to date, encompassing the work of five high-volume centers, Khalifeh et al. reviewed 943 patients who underwent RAPN. The PSM rate was 2.2%. Cases of PSM had a higher rate of recurrence and metastasis (p < 0.001). In fact, a PSM conferred an 18.4-fold higher hazard ratio for recurrence. Other authors have demonstrated similar oncologic control (55, 58, 64-66). Furthermore, in a review of modern, large RAPN series, Benway and Bhayani found that amongst >1600 patients, only seven recurrences (< 1%) were detected. The cumulative PSM rate was 2.7% (67). In comparison, PSM rates as reported by Gill et al. for LPN and OPN were 2.9 and 1.3%, respectively (17).

Limited data is available regarding long-term oncologic outcomes in RAPN given its relatively recent dissemination. In 2013, Khalifeh et al. assessed 427 patients with a mean tumor size of 3.0 ± 1.6 cm (68). Seventy patients had greater than three years of follow-up and 134 had at least two years. Overall survival was 97.0% at three years and 90.2% at five years. Cancer-specific survival was 98.9% at both three and five year follow-up. Kylo et al. demonstrated similar outcomes in a study of 124 patients with median follow-up of 29 months (64). Three-year disease-free survival was 94.9% and cancer-specific survival was 99.1% based on Kaplan-Meier analysis. Long-term oncologic control with RAPN appears sound.

Renal function

As mentioned above, it is known that RN is linked to increased chronic renal insufficiency (9, 10, 69). PN is intended to mitigate the unnecessary damage to a patient’s renal function that RN invokes. The first international, multi-center study of 183 patients showed no significant postoperative change in estimated
Table 1. Ten largest robotic partial nephrectomy series*

| Ref | N   | Mean tumor size (cm) | Mean operative time (min) | Mean WIT (min) | Mean EBL (mL) | PSM (%) | Complications (%) | Mean LOS (days) | Mean f/u (months) | Mean Nephrometry |
|-----|-----|----------------------|---------------------------|----------------|---------------|---------|-----------------|----------------|------------------|------------------|
| 94  | 148 | 2.8                  | 197                       | 27.8           | 183           | 4.0     | 6.1             | 1.9            | 18               | NR               |
| 70  | 183 | 2.9                  | 210                       | 23.9           | 132           | 3.8     | 9.8             | NR             | 16†              | NR               |
| 74  | 195 | 2.4                  | 135†                      | 23.8           | 200           | 1.5     | NR              | NR             | 31.1             | NR               |
| 95  | 240 | 3.0†                 | 161†                      | 20†            | 100†          | 6.7     | 32.6            | NR             | 4†               | NR               |
| 96† | 267 | 2.7†                 | 162†                      | 17†            | 100†          | 2.4     | 17.6            | NR             | 10.6†            | 6†               |
| 97‡ | 268 | 2.9†                 | 205†                      | 18†            | 75†           | NR      | 22              | 2.8            | 15.4             | NR               |
| 91  | 347 | 2.8†                 | 112 (console time)        | 18†            | 100           | 3.6     | 14.7            | NR             | NR               | PADUA score 8†   |
| 98  | 413 | 3.2                  | 191                       | 21             | 200           | NA      | 4.3 (major)     | 3.6            | NA               | NA               |
| 99 (non-hilar vs. hilar) | 405 vs 41 | 2.6 vs 3.2† | 187.4 vs 194.5 | 19.6 vs 26.3 | 208.2 vs 262.2 | 1.5 vs 2.4 | 5.4 vs 2.4 | 2.9 vs 2.9 | NR               | NR               |
| 81  | 886 | 3.0                  | 183.6                     | 18.8           | 100†          | NR      | 139(15.6)      | NR             | 13.3             | 6.9              |

* The most recent report of each cohort is presented.
† Median
¥ Completely endophytic tumors excluded
§ Includes only patients < 70 years old
WIT = warm ischemia time, EBL = Estimated blood loss, LOS = length of stay, PSM = positive surgical margin, f/u = follow-up, NR = not recorded, NA = not available

glomerular filtration rate (eGFR; 82.2 vs. 79.4 mL/min/1.73 m², p = 0.74) up to 26 months following RAPN (70). It should be noted that OPN is also comparable to clamped RAPN in terms of percent changes in eGFR (71). Zargar et al. assessed 99 patients with mercapto-acetyltriglycine renal scan after RAPN (72). They found the median (interquartile range) of total eGFR preservation and ipsilateral renal function (IRF) to be 83.8 (75.2 - 94.1)% and 72.0 (60.3-81.0)%, respectively. In their cohort, volume of normal parenchyma removed, WIT > 30 minutes, body mass index, and the operated kidney’s preoperative eGFR were predictive of IRF preservation. Although the kidney on which was operated will be affected, Kumar et al. reported an interesting finding (73). It seems performing RAPN on patients with baseline chronic kidney disease (CKD) may be especially beneficial relative to other treatments. It has been shown that those with baseline CKD have a smaller magnitude of renal function decline compared to those with normal preoperative renal function.

Long-term depictions of change in renal function are developing. In a report from 2015, Kim et al. found that patients undergoing RAPN recovered more renal function in the long-term (60 months) than those who underwent LPN (74). The pattern of renal function recovery included a significant depression of renal function at ~3-9 months, and a gradual increase after reaching nadir. In the RAPN group, the nadir was 91.2% of the baseline eGFR. The renal function recovered to 95.2% of the preoperative value at 60 months.

Tumors greater than 4 cm

As experience with RAPN has accumulated, the indications have expanded to larger tumors. Petros et al. retrospectively reviewed 445 consecutive patients from four centers; 85 patients had tumors > 4 cm (stage T1b) (75). Functional outcomes and complications were similar to those with smaller tumors, and there were no positive margins. Other series of non-robotic PN have demonstrated similar overall and cancer-specific survival for PN versus RN in T1b tumors (76,77). But,
given the 2-5% lifetime incidence of contralateral renal cancer (78), it is prudent to consider PN, and RAPN, for appropriate patients.

Complications

Early series of RAPN reported rates of complications as high as 20% (21). The complication rates in contemporary RAPN series, even those including large, complex tumors, remain similar (8.6-20.0%) (57-59). These overall complication rates are comparable to the reported complication rates of 13.7 and 18.6% in patients undergoing OPN and LPN, respectively (17). Furthermore, a study by Simhan et al. found a similar major and minor complication rate between RAPN and OPN (71). In a multi-institutional study of 450 patients who underwent RAPN, complications were stratified using the Clavien-Dindo classification system (79, 80). Seventy-one patients experienced a complication (16%), with eight intraoperative and 65 postoperative complications; 54 complications were classified as Clavien Grade I or II (12%), which required conservative management only, whereas 17 were Clavien Grade III or IV (4%) and necessitated subsequent intervention. This is comparable to another multi-institutional study of 886 consecutive cases of RAPN performed at five U.S. centers which reported an overall complication rate of 15.6%, with intraoperative and postoperative complication rates of 2.6 and 13.0%, respectively. Postoperative complications were classified as Clavien grade I-II in 77.0% of cases and grade III-IV in 23.0% (81). Updated data from this series now includes 1838 patients, an intraoperative complication rate of 2.1% and overall complication rate of 17.2%. The majority of the complications were considered Clavien 1-2 (72.5%) (82). Of all complications, hemorrhagic complications occurred in 71 (24.9%) patients, genitourinary in 72 (25.2%), pulmonary in 38 (12.4%), cardiovascular in 34 (11.1%), gastrointestinal in 26 (8.5%), infectious in 22 (7.2%) and other in 21 (6.9%) patients. Fifty-one patients (2.7%) required perioperative transfusion, 10 (0.05%) required angioembolization, and 5 (0.2%) required surgical exploration for postoperative hemorrhage. Urine leaks developed in 13 (0.7%) of patients and 10 (0.05%) patients developed postoperative acute renal failure.

Hemorrhage

Published postoperative transfusion rates for RAPN range from 3 to 10%, which are comparable to the 5.8 and 3.4% rates for LPN and OPN, respectively (83). Furthermore, the rates of postoperative hemorrhage after minimally invasive PN are relatively low (<5%) and are similar between laparoscopic and robotic series, with a rare need for angioembolization (0.4%) (84, 85).

In one multi-institutional analysis of RAPN complications, the reported postoperative hemorrhage rate for RAPN was 5.8%, and the intraoperative hemorrhage rate was 1.0% (hemorrhage was defined as bleeding requiring blood transfusion or therapeutic intervention) (81). Many postoperative hemorrhages arise from pseudoaneurysm or arteriovenous fistula formation which may result in delayed postoperative hemorrhage, often presenting several weeks after discharge (57).

Intraoperative techniques used to decrease the risk of hemorrhage include the use of a deoxidized cellulose bolsters during renorrhaphy to provide compressive hemostasis (86); the use of a gelatin matrix thrombin sealant, which has been reported to reduce postoperative hemorrhage from 11.8% to 3.2% (87). The use of "sliding-clip" renorrhaphy, and the use of barbed V-Loc sutures (Covidien, Mansfield, MA) during reconstruction, allows the even distribution of tension across the surgical bed to control transected vessels and reduce the likelihood of postoperative bleeding (25). Although not presently validated, checklists to prepare for and manage intraoperative hemorrhage are available (88).

Urine leak

Urine leak was formerly the most common postoperative complication of OPN with a rate of 17.4% (89), adding significant morbidity to the procedure. Minimally invasive approaches afford lower rates of urine leak when compared to open
approaches (41). Reported rates of urine leak range from 0.6 – 2.5% (90). The lowest reported leak rate of 0.6% comes from a RAPN cohort of 347 patients described by Ficarra et al. (91).

**Cost**

RAPN is considerably more expensive compared to LPN in the typical setting. However, in an efficient hospital and surgical system, the difference can be minimized to just $334 per case (92). Furthermore, as many studies suggest that complications are lower in RAPN compared to LPN, it may be reasonable to expect that total costs would narrow further. As health policy changes, penalties for readmissions may be assessed by the Center for Medicare and Medicaid Services. Such potential policy would make those operations with fewer readmissions due to complications more prudent (93).

**Conclusion**

PN offers improved renal function and similar survival to RN. RAPN facilitates the performance of minimally invasive PN due to its short learning curve. The breadth of cases undertaken for RAPN continues to expand with enduring success. Innovation continues to make RAPN an attractive and relatively facile technology with which to provide superb care for patients with renal tumors. Future research will be directed toward refining techniques to minimize WIT and to improve upon the RAPN’s consistency in achieving the “trifecta.”

**Conflict of interest**

None

**References**

1. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245-57. Doi: http://dx.doi.org/10.1038/nrurol.2010.46.

2. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol. 2002;167(1):57-60. Doi: http://dx.doi.org/10.1016/S0022-5347(05)65382-7

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. Doi: http://dx.doi.org/10.3322/caac.21254

4. Russo P. Renal cell carcinoma: presentation, staging, and surgical treatment. Semin Oncol. 2000;27(2):160-76.

5. Kim SP, Murad MH, Thompson RH, Boorjian SA, Weight CJ, Han LC, Erwin PJ, Costello BA, Chow GK, Leibovich BC. Comparative Effectiveness for Survival and Renal Function of Partial and Radical Nephrectomy for Localized Renal Tumors: A Systematic Review and Meta-Analysis. J Urol. 2012 Oct 18. pii: S0022-5347(12)05382-7. Doi: http://dx.doi.org/10.1016/j.juro.2012.10.026.

6. Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol. 2014;65(2):372-7. Doi: http://dx.doi.org/10.1016/j.eururo.2013.06.044

7. Thompson RH. Partial versus radical nephrectomy: the debate regarding renal function ends while the survival controversy continues. Eur Urol. 2014;65(2):378-9; discussion 379-80. Doi: http://dx.doi.org/10.1016/j.eururo.2013.07.036

8. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med.2004;351(13):1296-305. Doi: http://dx.doi.org/10.1056/NEJMoa041031

9. Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, Blute ML. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008;179(2):468-71; discussion 472-3.

10. Weight CJ, Lieser G, Larson BT, Gao T, Lane BR, Campbell SC, Gill IS, Novick AC, Fergany AF. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated
benign renal tumours. Eur Urol. 2010;58(2):293-8. 
Doi: http://dx.doi.org/10.1016/j.eururo.2010.04.033

11. Van Poppel H et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011 Apr;59(4):543-52. 
Doi: http://dx.doi.org/10.1016/j.eururo.2010.12.013

12. Campbell SC et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4):1271-9. 
Doi: http://dx.doi.org/10.1016/j.juro.2009.07.004

13. Bjurlin MA, Walter D, Taksler GB, Huang WC, Wysock JS, Sivarajan G, Loeb S, Taneja SS, Makarov DV. National trends in the utilization of partial nephrectomy before and after the establishment of AUA guidelines for the management of renal masses. Urology. 2013;82(6):1283-1289. 
Doi: http://dx.doi.org/10.1016/j.urology.2013.07.068

14. Thompson RH, Kaag M, Vickers A, Kundu S, Bernstein M, Lowrance W, Galvin D, Dalbagni G, Touijer K, Russo P. Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol. 2009 Mar;181(3):993-7. 
Doi: http://dx.doi.org/10.1016/j.juro.2008.11.017

15. Gautam G, Benway BM, Bhayani SB, Zorn KC. Robot-assisted partial nephrectomy: current perspectives and future prospects. Urology. 2009;74(4):735-40. 
Doi: http://dx.doi.org/10.1016/j.urology.2009.03.041

16. Patel HD, Mullins JK, Pierorazio PM, Jayram G, Cohen JE, Matlaga BR, Allaf ME. Trends in renal surgery: robotic technology is associated with increased use of partial nephrectomy. J Urol. 2013;189(4):1229-35. 
Doi: http://dx.doi.org/10.1016/j.juro.2012.10.024

17. Gill IS et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007;178(1):41-6. 
Doi: http://dx.doi.org/10.1016/j.juro.2007.03.038

18. Lane BR, Gill IS. 7-year oncological outcomes after laparoscopic and open partial nephrectomy. J Urol. 2010;183(2):473-9. 
Doi: http://dx.doi.org/10.1016/j.juro.2009.10.023

19. Hollenbeck BK, Taub DA, Miller DC, Dunn RL, Wei JT. National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology. 2006;67(2):254-9. 
Doi: http://dx.doi.org/10.1016/j.urology.2005.08.050

20. Pierorazio PM, Patel HD, Feng T, Yohannan J, Hyams ES, Allaf ME. Robotic-assisted versus traditional laparoscopic partial nephrectomy: comparison of outcomes and evaluation of learning curve. Urology. 2011;78(4):813-9. 
Doi: http://dx.doi.org/10.1016/j.urology.2011.04.065

21. Porpiglia F, Volpe A, Billia M, Scarpa RM. Laparoscopic versus open partial nephrectomy: analysis of the current literature. Eur Urol. 2008;53(4):732-42; discussion 742-3. 
Doi: http://dx.doi.org/10.1016/j.eururo.2008.01.025

22. Hanzly M, Frederick A, Creighton T, Atwood K, Mehedint D, Kauffman EC, Kim HL, Schwab T. Learning Curves for Robotic-Assisted and Laparoscopic Partial Nephrectomy. J Endourol. 2015;29(3):297-303. 
Doi: http://dx.doi.org/10.1089/end.2014.0303.

23. Ghani KR, Sukumar S, Sammon JD, Rogers CG, Trinh QD, Menon M. Practice patterns and outcomes of open and minimally invasive partial nephrectomy since the introduction of robotic partial nephrectomy: results from the nationwide inpatient sample. J Urol. 2014;191(4):907-12. 
Doi: http://dx.doi.org/10.1016/j.juro.2013.10.099

24. Gettman MT, Blute ML, Chow GK, Neururer R, Bartsch G, Peschel R. Robot-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology. 2004;64(5):914-8. 
Doi: http://dx.doi.org/10.1016/j.urology.2004.06.049

25. Benway BM, Wang AJ, Cabello JM, Bhayani SB. Robotic partial nephrectomy with sliding-clip renorrhaphy: technique and outcomes. Eur Urol. 2009;55(3):592-9.
Doi: http://dx.doi.org/10.1016/j.eururo.2008.12.028

26. Dulabon LM, Stifelman MD. Laparoscopic and robotic partial nephrectomy. Retroperitoneal robotic and laparoscopic surgery. New York: Springer; 2011.

27. White MA et al. Robotic laparoendoscopic single-site radical nephrectomy: surgical technique and comparative outcomes. Eur Urol. 2011;59(3):815-22.
Doi: http://dx.doi.org/10.1016/j.eururo.2011.02.020

28. Weizer AZ, Palella GV, Montgomery JS, Miller DC, Hafez KS. Robot-assisted retroperitoneal partial nephrectomy: technique and perioperative results. J Endourol. 2011;25(4):553-7.
Doi: http://dx.doi.org/10.1089/end.2010.0481.

29. Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, Gill IS, Blute ML, Campbell SC. Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol. 2010 Sep;58(3):340-5.
Doi: http://dx.doi.org/10.1016/j.eururo.2010.05.047

30. Lane BR, Babineau DC, Poggio ED, Weight CJ, Larson BT, Gill IS, Novick AC. Factors predicting renal functional outcome after partial nephrectomy. J Urol. 2008;180(6):2363-8; discussion 2368-9.
Doi: http://dx.doi.org/10.1016/j.juro.2008.08.036

31. Becker F, Van Poppel H, Hakenberg OW, Stief C, Gill I, Guazzoni G, Montorsi F, Russo P, Stöckle M. Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol. 2009;56(4):625-34.
Doi: http://dx.doi.org/10.1016/j.juro.2009.07.016

32. Simmons MN, Hillyer SP, Lee BH, Fergany AF, Kaouk J, Campbell SC. Functional recovery after partial nephrectomy: effects of volume loss and ischemic injury. J Urol. 2012;187(5):1667-73.
Doi: http://dx.doi.org/10.1016/j.juro.2011.12.068

33. Nguyen MM, Gill IS. Halving ischemia time during laparoscopic partial nephrectomy. J Urol. 2008 Feb;179(2):627-32.
Doi: http://dx.doi.org/10.1016/j.juro.2007.09.086

34. Peyronnet B et al. Early unclamping technique during robot-assisted laparoscopic partial nephrectomy can minimise warm ischaemia without increasing morbidity. BJU Int. 2014;114(5):741-7.
Doi: http://dx.doi.org/10.1111/bju.12766

35. Gill IS, Eisenberg MS, Aron M, Berger A, Ukimura O, Patil MB, Campese V, Thangathurai D, Desai MM. “Zero ischaemia” partial nephrectomy: novel laparoscopic and robotic technique. Eur Urol. 2011;59(1):128-34.
Doi: http://dx.doi.org/10.1016/j.eururo.2010.10.002

36. Tanagho YS, Bhayani SB, Sandhu GS, Vaughn NP, Nepple KG, Fugenshau RS. Renal functional and perioperative outcomes of off-clamp versus clamped robot-assisted partial nephrectomy: matched cohort study. Urology. 2012 Oct;80(4):838-43.
Doi: http://dx.doi.org/10.1016/j.jurology.2012.04.074

37. Benway BM, Cabello JM, Fugenshau RS, Bhayani SB. Sliding-clip renorrhaphy provides superior closing tension during robot-assisted partial nephrectomy. J Endourol. 2010;24(4):605-8.
Doi: http://dx.doi.org/10.1089/end.2009.0244.

38. Ficarra V, Novara G, Secco S, Macchi V, Porzionario A, De Caro R, Artibani W. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol. 2009;56(5):786-93.
Doi: http://dx.doi.org/10.1016/j.juro.2009.07.040

39. Simmons MN, Ching CB, Samplaski MK, Park CH, Gill IS. Kidney tumor location measurement using the C index method. J Urol. 2010 May;183(5):1708-13.
Doi: http://dx.doi.org/10.1016/j.juro.2010.01.005

40. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182(3):844-53.
Doi: http://dx.doi.org/10.1016/j.juro.2009.05.035
41. Stroup SP, Palazzi K, Kopp RP, Mehrazin R, Santomauro M, Cohen SA, Patterson AL, L'Esperance JO, Derweesh IH. RENAL nephrometry score is associated with operative approach for partial nephrectomy and urine leak. Urology. 2012;80(1):151-6. Doi: http://dx.doi.org/10.1016/j.urology.2012.04.026

42. Canter D et al. Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology. 2011 Nov;78(5):1089-94. Doi: http://dx.doi.org/10.1016/j.urology.2011.04.035

43. Benadiba S1, Verin AL, Pignot G, Bessede T, Drai J, Bahi R, Toussile W, Rocher L, Patard JJ. Are Urologists and Radiologists Equally Effective in Determining the RENAL Nephrometry Score? Ann Surg Oncol. 2014 Nov 11. Doi: http://dx.doi.org/10.1245/s10434-014-14152-1

44. Ellison JS, Montgomery JS, Hafez KS, Miller DC, He C, Wolf JS Jr, Weizer AZ. Association of RENAL nephrometry score with outcomes of minimally invasive partial nephrectomy. Int J Urol. 2013;20(6):564-70. Doi: http://dx.doi.org/10.1111/j.1442-2042.2012.03222.x

45. Mayer WA, Godoy G, Choi JM, Goh AC, Bian SX, Link RE. Higher RENAL Nephrometry Score is predictive of longer warm ischemia time and collecting system entry during laparoscopic and robotic-assisted partial nephrectomy. Urology. 2012;79(5):1052-6. Doi: http://dx.doi.org/10.1016/j.urology.2012.01.048

46. Bruner B, Breaux RH, Lohse CM, Leibovich BC, Blute ML. Renal nephrometry score is associated with urine leak after partial nephrectomy. BJU Int. 2011;108(1):67-72. Doi: http://dx.doi.org/10.1111/j.1445-410X.2010.09837.x

47. Hew MN1, Baseskioglu B, Barwari K, Axwijk PH, Can C, Horenblad S, Bex A, Rosette JJ, Pes M. Critical appraisal of the PADUA classification and assessment of the R.E.N.A.L. nephrometry score in patients undergoing partial nephrectomy. J Urol. 2011 Jul;186(1):42-6. Doi: http://dx.doi.org/10.1016/j.juro.2011.03.020

48. Larson JA, Kaouk JH, Stifelman MD, Rogers CG, Alkil ME, Potretzke A, Marshall S, Zargar H, Ball MW, Bhayani SB. Nonmodifiable Factors and Complications Contribute to Length of Stay in Robot-Assisted Partial Nephrectomy. J Endourol. 2014 Dec 30.

49. Simmons MN, Hillyer SP, Lee BH, Fergany AF, Kaouk J, Campbell SC. Nephrometry score is associated with volume loss and functional recovery after partial nephrectomy. J Urol. 2012;188(1):39-44. Doi: http://dx.doi.org/10.1016/j.juro.2012.02.2574

50. Mufarrij PW, Krane LS, Rajamahanty S, Hemal AK. Does nephrometry scoring of renal tumors predict outcomes in patients selected for robot-assisted partial nephrectomy? J Endourol. 2011 Oct;25(10):1649-53. Doi: http://dx.doi.org/10.1089/end.2011.0003

51. Sea JC, Bahler CD, Mendonsa E, Lucas SM, Sundaram CP. Comparison of measured renal tumor size versus R.E.N.A.L. nephrometry score in predicting patient outcomes after robot-assisted laparoscopic partial nephrectomy. J Endourol. 2013;27(12):1471-6. Doi: http://dx.doi.org/10.1089/end.2013.0202

52. Rogers CG, Laungani R, Bhandari A, Krane LS, Eun D, Patel MN, Boris R, Shrivastava A, Menon M. Maximizing console surgeon independence during robot-assisted renal surgery by using the Fourth Arm and TilePro. J Endourol. 2009;23(1):115-21. Doi: http://dx.doi.org/10.1089/end.2008.0416

53. McClintock TR, Bjurlin MA1, Wysock JS1, Borofsky MS1, Marien TP1, Okoro C1, Stifelman MD. Can selective arterial clamping with fluorescence imaging preserve kidney function during robotic partial nephrectomy? Urology. 2014;84(2):327-32. Doi: http://dx.doi.org/10.1016/j.urology.2014.02.044

54. Zargar H, Alkil ME, Bhayani S, Stifelman M, Rogers C, Ball M, Larson J, Marshall S, Kumar R, Kaouk J. Trifecta and optimal peri-operative outcomes of robotic and laparoscopic partial nephrectomy in surgical treatment of small renal masses: A multi-institutional study. BJU Int. 2014 Sep 15. Doi: http://dx.doi.org/10.1111/bju.12933

55. Aron M, Koenig P, Kaouk JH, Nguyen MM, Desai MM, Gill IS. Robotic and laparoscopic partial nephrectomy: a matched-pair comparison from a high-volume centre. BJU Int. 2008;102(1):86-92.
56. Deane LA et al. Robotic versus standard laparoscopic partial/wedge nephrectomy: a comparison of intraoperative and perioperative results from a single institution. J Endourol. 2008;22(5):947-52. Doi: http://dx.doi.org/10.1089/end.2007.0376.

57. Benway BM, Bhayani SB, Rogers CG, Dulabon LM, Patel MN, Lipkin M, Wang AJ, Stifelman MD. Robot assisted partial nephrectomy versus laparoscopic partial nephrectomy for renal tumors: a multi-institutional analysis of perioperative outcomes. J Urol. 2009;182(3):866-72. Doi: http://dx.doi.org/10.1016/j.juro.2009.05.037

58. Wang AJ, Bhayani SB. Robotic partial nephrectomy versus laparoscopic partial nephrectomy for renal cell carcinoma: single-surgeon analysis of >100 consecutive procedures. Urology. 2009;73(2):306-10. Doi: http://dx.doi.org/10.1016/j.urology.2008.09.049

59. Haber GP, White WM, Crouzet S, White MA, Forest S, Autorino R, Kaouk JH. Robotic versus laparoscopic partial nephrectomy: single-surgeon matched cohort study of 150 patients. Urology. 2010;76(3):754-8. Doi: http://dx.doi.org/10.1016/j.urology.2010.03.058

60. Williams SB, Kacker R, Alemozaffar M, Francisco IS, Mehaber J, Wagner AA. Robotic partial nephrectomy versus laparoscopic partial nephrectomy: a single laparoscopic trained surgeon’s experience in the development of a robotic partial nephrectomy program. World J Urol. 2013;31(4):793-8. Doi: http://dx.doi.org/10.1007/s00345-011-0648-5

61. Choi JE, You JH, Kim DK, Rha KH, Lee SH. Comparison of Perioperative Outcomes Between Robotic and Laparoscopic Partial Nephrectomy: A Systematic Review and Meta-analysis. Eur Urol. 2015 Jan 6. pii: S0302-2838(14)01294-9. Doi: http://dx.doi.org/10.1016/j.eururo.2014.12.028

62. Hung AJ, Cai J, Simmons MN, Gill IS. “Trifecta” in partial nephrectomy. J Urol. 2013;189(1):36-42. Doi: http://dx.doi.org/10.1016/j.juro.2012.09.042

63. Azhar RA, Gill IS, Aron M. Robotic nephron-sparing surgery for renal tumors: Current status. Indian J Urol. 2014;30(3):275-82. Doi: http://dx.doi.org/10.4103/0970-1356/135667.

64. Kyllö RL, Tanagho YS, Kaouk JH, et al. Prospective multi-center study of oncologic outcomes of robot-assisted partial nephrectomy for pT1 renal cell carcinoma. BMC Urol. 2012;12:11. Doi: http://dx.doi.org/10.1186/1471-2490-12-11

65. Rogers CG, Metwalli A, Blatt AM, Bratslavsky G, Menon M, Linehan WM, Pinto PA. Robotic partial nephrectomy for renal hilar tumors: a multi-institutional analysis. J Urol. 2008;180(6):2353-6. Doi: http://dx.doi.org/10.1016/j.juro.2008.08.022

66. Patel MN, Krane LS, Bhandari A, Laungani RG, Shrivastava A, Siddiqui SA, Menon M, Rogers CG. Robotic partial nephrectomy for renal tumors larger than 4 cm. Eur Urol. 2010;57(2):310-6. Doi: http://dx.doi.org/10.1016/j.eururo.2009.11.024

67. Benway BM, Bhayani SB. Surgical outcomes of robot-assisted partial nephrectomy. BJU Int. 2011;108(6 Pt 2):955-61. Doi: http://dx.doi.org/10.1111/j.1464-410X.2011.10470.x

68. Khalifeh A, Autorino R, Eyraud R, Samarasekera D, Laydner H, Panumatrassamee K, Stein RJ, Kaouk JH. Three-year oncologic and renal functional outcomes after robot-assisted partial nephrectomy. Eur Urol. 2013;64(5):744-50. Doi: http://dx.doi.org/10.1016/j.eururo.2013.03.052

69. Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, Scardino PT, Russo P. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006;7(9):735-40. Doi: http://dx.doi.org/10.1016/S1470-2045(06)70803-8

70. Benway BM, Bhayani SB, Rogers CG, Porter JR, Buffi NM, Figenshau RS, Mottrie A. Robot-
assisted partial nephrectomy: an international experience. Eur Urol. 2010;57(5):815-20.

Doi: http://dx.doi.org/10.1016/j.eururo.2010.01.011

71. Simhan J et al. Perioperative outcomes of robotic and open partial nephrectomy for moderately and highly complex renal lesions. J Urol. 2012;187(6):2000-4.

Doi: http://dx.doi.org/10.1016/j.juro.2012.01.064

72. Zargar H, Akca O, Autorino R, Brandao LF, Laydner H, Krishnan J, Samaratseker D, Stein RJ, Kaouk JH. Ipsilateral renal function preservation after robot-assisted partial nephrectomy (RAPN): an objective analysis using mercapto-acetyltriglycine (MAG3) renal scan data and volumetric assessment. BJU Int. 2014 Jun 6.

Doi: http://dx.doi.org/10.1111/bju.12825

73. Kumar RK et al. Robot-assisted partial nephrectomy in patients with baseline chronic kidney disease: a multi-institutional propensity score-matched analysis. Eur Urol. 2014;65(6):1205-10.

Doi: http://dx.doi.org/10.1016/j.eururo.2013.12.004

74. Kim JH, Park YH, Kim YJ, Kang SH, Byun SS, Kwak C, Hong SH. Perioperative and long-term renal functional outcomes of robotic versus laparoscopic partial nephrectomy: a multicenter matched-pair comparison. World J Urol. 2015 Jan 14.

Doi: http://dx.doi.org/10.1007/s00345-015-1488-5

75. Petros F, Sukumar S, Haber GP, Dulabon L, Bhayani S, Stifelman M, Kaouk J, Rogers C. Multi-institutional analysis of robot-assisted partial nephrectomy for renal tumors >4 cm versus <= 4 cm in 445 consecutive patients. J Endourol. 2012;26(6):642-6.

Doi: http://dx.doi.org/10.1089/end.2011.0340.

76. Leibovich BC, Blute M, Cheville JC, Lohse CM, Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol. 2004;171(3):1066-70.

Doi: http://dx.doi.org/10.1097/01.ju.000013274.40885.db

77. Badalato GM, Kates M, Wisnivesky JP, Choudhury AR, McKiernan JM. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach. BJU Int. 2012;109(10):1457-62.

Doi: http://dx.doi.org/10.1111/j.1464-410X.2011.10597.x

78. Bani-Hani AH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML. Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. J Urol. 2005;173(2):391-4.

Doi: http://dx.doi.org/10.1097/01.ju.0000148951.7353.8b

79. spana G1, haber GP, dulabon LM, petros F, Rogers CG, Bhayani SB, Stifelman MD, kaouk JH. Complications after robotic partial nephrectomy at centers of excellence: multi-institutional analysis of 450 cases. J Urol. 2011;186(2):417-21.

Doi: http://dx.doi.org/10.1016/j.juro.2011.03.127

80. Clavien PA et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187-96.

Doi: http://dx.doi.org/10.1097/SLA.0b013e3181b3ca2

81. Tanagho YS, Kaouk JH, Allaf ME, Rogers CG, Stifelman MD, Kaczmarek BF, Hillyer SP, Mullins JK, Chiu Y, Bhayani SB. Perioperative complications of robot-assisted partial nephrectomy: analysis of 886 patients at 5 United States centers. Urology. 2013;81(3):573-9.

Doi: http://dx.doi.org/10.1016/j.urology.2012.10.067

82. Larson JA, Kaouk JH, Zargar H, et al. Complications after robotic-assisted partial nephrectomy at 5 United States centers: analysis of 1838 cases. American Urological Association; May 15-19, 2015; New Orleans, LA.

83. Cha EK, Lee DJ, Del Pizzo JJ. Current status of robotic partial nephrectomy (RPN). BJU Int. 2011;108(6 Pt 2):935-41.

Doi: http://dx.doi.org/10.1111/j.1464-410X.2011.10556.x

84. Simmons MN, Gill IS. Decreased complications of contemporary laparoscopic partial nephrectomy: use of a standardized
reporting system. J Urol. 2007 Jun;177(6):2067-73. Doi: http://dx.doi.org/10.1016/j.juro.2007.01.129

85. Ukimura O, Nakamto M, Gill IS. Three-dimensional reconstruction of renovascular-tumor anatomy to facilitate zero-ischemia partial nephrectomy. Eur Urol. 2012;61(1):211-7. Doi: http://dx.doi.org/10.1016/j.eururo.2011.07.068

86. Haber GP, Gill IS. Laparoscopic partial nephrectomy: contemporary technique and outcomes. Eur Urol. 2006;49(4):660-5. Doi: http://dx.doi.org/10.1016/j.eururo.2006.02.001

87. Gill IS, Ramani AP, Spaliviero M, Xu M, Finelli A, Kaouk JH, Desai MM. Improved hemostasis during laparoscopic partial nephrectomy using gelatin matrix thrombin sealant. Urology. 2005 Mar;65(3):463-6. Doi: http://dx.doi.org/10.1016/j.urology.2004.10.030

88. Nepple KG, Sandhu GS, Rogers CG, Allaf ME, Kaouk JH, Figenshau RS, Stifelman MD, Bhayani SB. Description of a multicenter safety checklist for intraoperative hemorrhage control while clamped during robotic partial nephrectomy. Patient Saf Surg. 2012;6:8 Doi: http://dx.doi.org/10.1186/1754-9493-6-8

89. Campbell SC, Novick AC, Streeem SB, Klein E, Licht M. Complications of nephron sparing surgery for renal tumors. J Urol. 1994;151(5):1177-80.

90. Tomaszewski JJ, Smallone MC, Cung B, Li T, Mehranzin R, Kutikov A, Canter DJ, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Internal validation of the renal pelvic score: a novel marker of renal pelvic anatomy that predicts urine leak after partial nephrectomy. Urology. 2014;84(2):351-7. Doi: http://dx.doi.org/10.1016/j.urology.2014.05.001

91. Ficarra V, Bhayani S, Porter J, Buffi N, Lee R, Cestari A, Mottrie A. Predictors of warm ischemia time and perioperative complications in a multicenter, international series of robot-assisted partial nephrectomy. Eur Urol. 2012;61(2):395-402. Doi: http://dx.doi.org/10.1016/j.eururo.2011.10.046

92. Hyams E, Pierorazio P, Mullins JK, Ward M, Allaf M. A comparative cost analysis of robot-assisted versus traditional laparoscopic partial nephrectomy. J Endourol. 2012;26(7):843-7. Doi: http://dx.doi.org/10.1089/end.2011.0522

93. Brandao LF et al. 30-day hospital readmission after robotic partial nephrectomy—are we prepared for Medicare readmission reduction program? J Urol. 2014;192(3):677-81. Doi: http://dx.doi.org/10.1016/j.juro.2014.02.009

94. Rogers CG, Menon M, Weise ES, Gettman MT, Frank I, Shephard DL, Abrahams HM, Green JM, Savatta DJ, S. B. Bhayani SB. Robotic partial nephrectomy: a multi-institutional analysis. J Robot Surg. 2008;2(3):141-43. Doi: http://dx.doi.org/10.1007/s11701-008-0098-2

95. Mathieu R1, Verhoest G, Droupy S, de la Taille A, Bruyere F, Doumerc N, Risichmann P, Vaessen C, Roupret M, Bensalah K. Predictive factors of complications after robot-assisted laparoscopic partial nephrectomy: a retrospective multicentre study. BJU Int. 2013 Aug;112(4):E283-9. Doi: http://dx.doi.org/10.1111/bju.12222

96. Curtiss KM, Ball MW, Gorin MA, Harris KT, Pierorazio PM, Allaf ME. Perioperative Outcomes of Robotic Partial Nephrectomy for Intrarenal Tumors. J Endourol. 2015;29(3):293-6. Doi: http://dx.doi.org/10.1089/end.2014.0348

97. Sandberg JM, Krane LS, Hemal AK. A nonrandomized prospective comparison of robotic-assisted partial nephrectomy in the elderly to a younger cohort: an analysis of 339 patients with intermediate-term follow-up. Urology. 2014;84(4):838-43. Doi: http://dx.doi.org/10.1016/j.urology.2014.07.004

98. Eyraud R, Long JA, Guillotreau J, Stein RJ, Kaouk JH, Haber GP. [Robotic partial nephrectomy: five years retrospective analysis at a single center]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. Prog Urol. 2013 Apr;23(5):323-8. French. Doi: http://dx.doi.org/10.1016/j.purol.2012.10.016
99. Dulabon LM, Kaouk JH, Haber GP, Berkman DS, Rogers CG, Petros F, Bhayani SB, Stifelman MD. Multi-institutional analysis of robotic partial nephrectomy for hilar versus nonhilar lesions in 446 consecutive cases. Eur Urol. 2011;59(3):32530. Doi: http://dx.doi.org/10.1016/j.eururo.2010.11.017